Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 30,427 articles published since 2009
|||| 45 

These are the 30427 published articles about Pancreatic Neoplasms that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
251 Editorial Pancreatic EUS: the linear strikes back. 2015

Petrone, Maria Chiara / Arcidiacono, Paolo Giorgo. ·Endosonography Unit, Gastroenterology and Gastrointestinal Endoscopy Unit, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy. · Gastrointestinal Endoscopy Unit, Gastroenterology and Gastrointestinal Endoscopy Unit, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy. ·Gastrointest Endosc · Pubmed #26471999.

ABSTRACT: -- No abstract --

252 Editorial Better Biomarkers for Pancreatic Diseases. 2015

Whitcomb, David C. ·From the Departments of Medicine, Cell Biology & Molecular Physiology, and Human Genetics, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh/UPMC, Pittsburgh, PA. ·Pancreas · Pubmed #26465944.

ABSTRACT: -- No abstract --

253 Editorial Rac1 GTPase in pancreatic cancer. 2015

Yan, Ying / Ouellette, Michel M. ·Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA. · Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA. · Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE 68198, USA. ·Aging (Albany NY) · Pubmed #26420819.

ABSTRACT: -- No abstract --

254 Editorial Disconnect between EMT and metastasis in pancreas cancer. 2015

Whittle, Martin C / Hingorani, Sunil R. ·Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA. ·Oncotarget · Pubmed #26387140.

ABSTRACT: -- No abstract --

255 Editorial International guidelines for the management of pancreatic intraductal papillary mucinous neoplasms. 2015

Goh, Brian K P. ·Brian KP Goh, Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore 169856, Singapore. ·World J Gastroenterol · Pubmed #26379390.

ABSTRACT: The management of intraductal papillary mucinous neoplasms (IPMN) is presently evolving as a result of the improved understanding of the natural history and biological behavior of the different pancreatic cystic neoplasms; and better preoperative diagnosis of these neoplasms due to advancement in preoperative diagnostic tools. International consensus guidelines for the management of IPMN were first formulated in 2006 and subsequently revised in 2012. Both these guidelines were constructed based on expert opinion and not on robust clinical data. The main limitation of the original Sendai guidelines was that it had a low positive predictive value resulting in many benign neoplasms being resected. Hence, these guidelines were revised in 2012. However, although the updated guidelines resulted in an improvement in the positive predictive value over the Sendai Guidelines, the results of several studies validating these guidelines demonstrated that its positive predictive value remained low. Furthermore, although both guidelines were associated with high negative predictive values, several investigators have demonstrated that some malignant IPMNs may be missed. Finally, it is imperative to emphasize that major considerations when managing a patient with IPMN including the patient's surgical risk, life-expectancy and even cost of investigations are not taken into account in current guidelines. The management of a patient with IPMN should be individualized and tailored according to a patient's risk benefit profile for resection vs surveillance.

256 Editorial Targeting interleukin-17 receptors. 2015

Lee, Wen-Hwa / Wu, Heng-Hsiung / Huang, Chun-Kai. ·Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan. · Genomics Research Center, Academia Sinica, Taipei, Taiwan. ·Oncotarget · Pubmed #26285835.

ABSTRACT: -- No abstract --

257 Editorial Cyst fluid: moving beyond the carcinoembryonic antigen. 2015

Brugge, William R. ·Pancreas Biliary Center, Massachusetts General Hospital, Boston, Massachusetts, USA. ·Gastrointest Endosc · Pubmed #26264436.

ABSTRACT: -- No abstract --

258 Editorial Luciano Pavarotti (1935-2007). 2015

Rössner, S. ·Professor Emeritus. stephan@rossner.se. ·Obes Rev · Pubmed #26255651.

ABSTRACT: -- No abstract --

259 Editorial Pancreatic Cancer. 2015

Wolpin, Brian M. ·Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: bwolpin@partners.org. ·Hematol Oncol Clin North Am · Pubmed #26226911.

ABSTRACT: -- No abstract --

260 Editorial Intraductal Radiofrequency Ablation (RFA) for Pancreatic Cancer: Getting in Under the Wire? 2015

Brauer, Brian C. ·Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, 1635 Aurora Ct, Mailstop F-735, Room AIP 2.031, Aurora, CO, 80045, USA. Brian.brauer@ucdenver.edu. ·Dig Dis Sci · Pubmed #26209042.

ABSTRACT: -- No abstract --

261 Editorial Highlights of topic "Pancreatic neuroendocrine tumors update". 2015

Ito, Tetsuhide. ·Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. ·J Hepatobiliary Pancreat Sci · Pubmed #26199177.

ABSTRACT: -- No abstract --

262 Editorial Evaluating Research on the Safety of Medical Therapies: The Responsibility of Journals to the Health of the Public. 2015

Fontanarosa, Phil B / Bauchner, Howard / Golub, Robert M. ·Dr Fontanarosa is Executive Deputy Editor, Dr Bauchner is Editor in Chief, and Dr Golub is Deputy Editor, JAMA. ·JAMA · Pubmed #26197183.

ABSTRACT: -- No abstract --

263 Editorial The Safety of Prescription Drugs. 2015

Sharfstein, Joshua M / Kesselheim, Aaron S. ·Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. · The Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts3Harvard Medical School, Boston, Massachusetts. ·JAMA · Pubmed #26197182.

ABSTRACT: -- No abstract --

264 Editorial Current status and progress of pancreatic cancer in China. 2015

Lin, Quan-Jun / Yang, Feng / Jin, Chen / Fu, De-Liang. ·Quan-Jun Lin, Feng Yang, Chen Jin, De-Liang Fu, Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China. ·World J Gastroenterol · Pubmed #26185370.

ABSTRACT: Cancer is currently one of the most important public health problems in the world. Pancreatic cancer is a fatal disease with poor prognosis. As in most other countries, the health burden of pancreatic cancer in China is increasing, with annual mortality rates almost equal to incidence rates. The increasing trend of pancreatic cancer incidence is more significant in the rural areas than in the urban areas. Annual diagnoses and deaths of pancreatic cancer in China are now beyond the number of cases in the United States. GLOBOCAN 2012 estimates that cases in China account for 19.45% (65727/337872) of all newly diagnosed pancreatic cancer and 19.27% (63662/330391) of all deaths from pancreatic cancer worldwide. The population's growing socioeconomic status contributes to the rapid increase of China's proportional contribution to global rates. Here, we present an overview of control programs for pancreatic cancer in China focusing on prevention, early diagnosis and treatment. In addition, we describe key epidemiological, demographic, and socioeconomic differences between China and developed countries. Facts including no nationwide screening program for pancreatic cancer, delay in early detection resulting in a late stage at presentation, lack of awareness of pancreatic cancer in the Chinese population, and low investment compared with other cancer types by government have led to backwardness in China's pancreatic cancer diagnosis and treatment. Finally, we suggest measures to improve health outcomes of pancreatic cancer patients in China.

265 Editorial Protein kinase D enzymes: novel kinase targets in pancreatic cancer. 2015

Liou, Geou-Yarh / Storz, Peter. ·a Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. ·Expert Rev Gastroenterol Hepatol · Pubmed #26174103.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) is characterized by advanced stage desmoplastic tumors with a high prevalence of genetic abnormalities. Occurrence of PDA is linked to activating Kras mutations and aberrant epidermal growth factor receptor signaling, leading to additional activation of wild-type Kras. As Kras is difficult to target, there is a constant need to identify novel targets acting downstream of this molecule in driving the formation or progression of PDA. Recently, it was shown that protein kinase D enzymes not only are increasingly expressed in PDA but also causatively linked to the development and progression of this cancer. They act downstream of both mutant Kras and growth factors and therefore may represent ideal novel targets.

266 Editorial IER3 in pancreatic carcinogenesis. 2015

Molejon, Maria Inés / Iovanna, Juan Lucio. ·Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France. ·Oncotarget · Pubmed #26158545.

ABSTRACT: -- No abstract --

267 Editorial Very long-term survival in pancreatic cancer. 2015

Molin, Marco Dal / Wood, Laura D. ·Gastrointestinal and Liver Pathology Department, Johns Hopkins University, Baltimore, MD, USA. ·Aging (Albany NY) · Pubmed #26143583.

ABSTRACT: -- No abstract --

268 Editorial Pulling the Trigger on Pancreatic Cysts. 2015

Othman, Mohamed O / Topazian, Mark D. ·Baylor College of Medicine, Houston, Texas. · Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota. ·Clin Gastroenterol Hepatol · Pubmed #26122760.

ABSTRACT: -- No abstract --

269 Editorial Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. 2015

Evans, Douglas B / George, Ben / Tsai, Susan. ·Pancreatic Cancer Program, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA. devans@mcw.edu. · Pancreatic Cancer Program, Department of Medicine, The Medical College of Wisconsin, Milwaukee, WI, USA. · Pancreatic Cancer Program, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA. ·Ann Surg Oncol · Pubmed #26122369.

ABSTRACT: -- No abstract --

270 Editorial Highlights of topic "Recent advances in hepato-biliary-pancreatic science". 2015

Fujimoto, Jiro. ·Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. sfujimo@hyo-med.ac.jp. ·J Hepatobiliary Pancreat Sci · Pubmed #26100098.

ABSTRACT: -- No abstract --

271 Editorial Prognostication and response assessment in liver and pancreatic tumors: The new imaging. 2015

De Robertis, Riccardo / Tinazzi Martini, Paolo / Demozzi, Emanuele / Puntel, Gino / Ortolani, Silvia / Cingarlini, Sara / Ruzzenente, Andrea / Guglielmi, Alfredo / Tortora, Giampaolo / Bassi, Claudio / Pederzoli, Paolo / D'Onofrio, Mirko. ·Riccardo De Robertis, Emanuele Demozzi, Gino Puntel, Mirko D'Onofrio, Department of Radiology, Verona Comprehensive Cancer Network, G.B. Rossi Hospital, University of Verona, 37134 Verona, Italy. ·World J Gastroenterol · Pubmed #26078555.

ABSTRACT: Diffusion-weighted imaging (DWI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perfusion computed tomography (CT) are technical improvements of morphologic imaging that can evaluate functional properties of hepato-bilio-pancreatic tumors during conventional MRI or CT examinations. Nevertheless, the term "functional imaging" is commonly used to describe molecular imaging techniques, as positron emission tomography (PET) CT/MRI, which still represent the most widely used methods for the evaluation of functional properties of solid neoplasms; unlike PET or single photon emission computed tomography, functional imaging techniques applied to conventional MRI/CT examinations do not require the administration of radiolabeled drugs or specific equipments. Moreover, DWI and DCE-MRI can be performed during the same session, thus providing a comprehensive "one-step" morphological and functional evaluation of hepato-bilio-pancreatic tumors. Literature data reveal that functional imaging techniques could be proposed for the evaluation of these tumors before treatment, given that they may improve staging and predict prognosis or clinical outcome. Microscopic changes within neoplastic tissues induced by treatments can be detected and quantified with functional imaging, therefore these techniques could be used also for post-treatment assessment, even at an early stage. The aim of this editorial is to describe possible applications of new functional imaging techniques apart from molecular imaging to hepatic and pancreatic tumors through a review of up-to-date literature data, with a particular emphasis on pathological correlations, prognostic stratification and post-treatment monitoring.

272 Editorial The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors? 2015

Funel, Niccola. · ·Epigenomics · Pubmed #26077422.

ABSTRACT: -- No abstract --

273 Editorial Celiac plexus neurolysis and pancreatic cancer survival: Back to the future? 2015

Sahai, Anand V. ·Division of Gastroenterology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. ·Gastrointest Endosc · Pubmed #26074036.

ABSTRACT: -- No abstract --

274 Editorial New insights into plasticity of pancreatic cancer: cancer to acinar cell reprogramming by the basic helix-loop-helix transcription factor E47. 2015

Bailey, Jennifer M / Hendley, Audrey M / Maitra, Anirban. ·From the *Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Health Science Center at Houston; and †Departments of Pathology and Molecular Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. ·Pancreas · Pubmed #26061556.

ABSTRACT: -- No abstract --

275 Editorial Predicting a response to FOLFIRINOX in pancreatic cancer. 2015

Nipp, Ryan D / Ryan, David P. ·Massachusetts General Hospital Cancer Center rnipp@partners.org. · Massachusetts General Hospital Cancer Center. ·J Natl Cancer Inst · Pubmed #26025325.

ABSTRACT: -- No abstract --

Back · Next